Russia's cancer drug market to grow to $163 million

Wednesday, December 14, 2011 12:48 PM

Decision Resources, a research and advisory firm for pharmaceutical and healthcare issues, has found that the Russian market for non-small-cell lung cancer therapies will grow 3% annually from 2010 to 2015 to $163 million in 2015. According to the Emerging Markets report, Non-Small-Cell Lung Cancer in Russia, an increase in the incident population, gradually increasing use of higher-priced chemotherapies and the introduction of several premium-priced agents will promote this growth.

The incidence of non-small-cell lung cancer in Russia is the highest among the BRIC (Brazil, Russia, India, China) markets and is comparable to that of the United Kingdom and the United States. Increasing risk of non-small-cell lung cancer due to increasing smoking prevalence in men, in conjunction with an aging population, will drive an increase in incident non-small-cell lung cancer cases in Russia.

As the incident non-small-cell lung cancer population grows in Russia, sales of most drug classes are expected to grow through 2015,” said Decision Resources analyst Natalia Reoutova. “The most dramatic growth will likely be seen in the kinase inhibitors drug class where three emerging agents—Boehringer Ingelheim’s Tovok, Pfizer’s dacomitinib and ArQule/Daiichi Sankyo/Kyowa Hakko Kirin’s tivantinib—should make their debut in or before 2015.”

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 27

NIH’s I-Corps boot camp aims to transform researchers into better businesspeople before they launch products

Covance, Frenova form partnership to share patient databases, find effective treatments for renal disease

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

CROs driving changes in patient recruitment
Data- and tech-aided enrollment services a competitive advantage

Trials with in-home nurses poised to grow
Higher expense, but may improve recruitment and retention for select trials

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs